TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21998319

Group type: EXPERIMENTAL
Intervention: TIA patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control subjects without symptomatic cardiovascular disease
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prediction analysis of 34 genes
Number of subjects: 26
Study: 18292453

Group type: EXPERIMENTAL
Intervention: Prehydration with 10 mL/kg of lactated Ringer's solution
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nonprehydration
Number of subjects: 68
Study: 16531162

Group type: EXPERIMENTAL
Intervention: DRSP/30EE
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DRSP/20EE
Number of subjects: 75

Group type: COMPARATOR
Intervention: DSG/30EE
Number of subjects: 75
Study: 14566163

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 79
Study: 11094598

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram kg‐1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fentanyl 2 micrograms kg‐1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 8931648

Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone 0.05 IU/kg/d
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8093338

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavior therapy
Number of subjects: 0
Study: 3739236

Group type: EXPERIMENTAL
Intervention: Moving sinusoidal grating with random contrast levels (5 to 82%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random changes in temporal frequency (2.25 to 8.25 Hz)
Number of subjects: 0
Study: 29574763

Group type: EXPERIMENTAL
Intervention: Glycine powder air-polishing (GPAP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) and air flushing with water (Control)
Number of subjects: 27
Study: 27167981

Group type: EXPERIMENTAL
Intervention: CHARM intervention (three-session GE+FP counseling)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1081
Study: 24962711

Group type: EXPERIMENTAL
Intervention: Pheburane(®) (Sodium Phenylbutyrate) taste-masked granules
Number of subjects: 0
Study: 22893691

Group type: EXPERIMENTAL
Intervention: SBAR exposure
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 21091062

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (6 times per week)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Conventional hemodialysis (3 times per week)
Number of subjects: 245
Study: 18723899

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 49
Study: 15902121

Group type: EXPERIMENTAL
Intervention: 200-microg buccal misoprostol
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 12626972

Group type: EXPERIMENTAL
Intervention: Hygroster HME (changed once a week)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Hygrobac HME (used for 1 week without change)
Number of subjects: 2
Study: 10489664

Group type: EXPERIMENTAL
Intervention: Tropisetron administration before and 4 days after cisplatin treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo administration after tropisetron before cisplatin treatment
Number of subjects: 98
Study: 9772614

Group type: EXPERIMENTAL
Intervention: Fumigation and inhalation of Huayin Powder
Number of subjects: 39

Group type: COMPARATOR
Intervention: Composite Qingdaiwan
Number of subjects: 39
Study: 1833088

Group type: EXPERIMENTAL
Intervention: GR32191B (80 mg orally before angioplasty and 80 mg/day orally for 6 months)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control (250 mg i.v. aspirin before angioplasty and placebo for 6 months)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: GR32191B
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control
Number of subjects: 522
Study: 6349666

Group type: EXPERIMENTAL
Intervention: Atrial synchronous pacing
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Physiological pacing mode
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 13
Study: 30968181

Group type: EXPERIMENTAL
Intervention: Unilateral stenting
Number of subjects: 72

Group type: COMPARATOR
Intervention: Bilateral stenting
Number of subjects: 72
Study: 30147355

Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 150 mg/day
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 300 mg/day
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 450 mg/day
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone (combined groups)
Number of subjects: 803
Study: 26615874

Group type: EXPERIMENTAL
Intervention: Self-directed learning (summative assessment)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Lectures (summative assessment)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Small-group peer-teaching (summative assessment)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Self-directed learning (formative assessment)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Lectures (formative assessment)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Small-group peer-teaching (formative assessment)
Number of subjects: 493
Study: 24374263

Group type: EXPERIMENTAL
Intervention: NBCA (Histoacryl)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: NBCA‐MS (Glubran2)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 83
Study: 22196510

Group type: EXPERIMENTAL
Intervention: Moxibustion therapy to CV4 and CV8 for 4 weeks (administered three times per week)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Simulated burning of moxibustion (control group)
Number of subjects: 45
Study: 18804894

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy (CT-RT) with cisplatin (CDDP) 60 mg/m², gemcitabine (GEM) 1g/m² on days 1 and 8, and vinorelbine (VNR) 25 mg/m² on days 1 and 8, followed by reduced dosage during radiotherapy (66Gy) in arm A.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy (CT-RT) with cisplatin (CDDP) 60 mg/m², gemcitabine (GEM) 1g/m² on days 1 and 8, and vinorelbine (VNR) 25 mg/m² on days 1 and 8, followed by reduced dosage during radiotherapy (66Gy) in arm B.
Number of subjects: 49
Study: 17710798

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 15071401

Group type: EXPERIMENTAL
Intervention: Aerosolized prostacyclin (epoprostenol sodium) at 30 ng x kg x min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Aerosolized normal saline (placebo)
Number of subjects: 14
Study: 11761344

Group type: EXPERIMENTAL
Intervention: High imagers (imagery ability)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Low imagers (imagery ability)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Relaxation condition
Number of subjects: 176
Study: 9914663

Group type: EXPERIMENTAL
Intervention: Subliminal priming of positive interpersonal expectations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal priming of negative interpersonal expectations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronically accessible interpersonal expectations (assessed by an attachment questionnaire)
Number of subjects: 0
Study: 7818813

Group type: EXPERIMENTAL
Intervention: HIV‐1 immunogen (100 micrograms or more)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HIV‐1 immunogen
Number of subjects: 48

Group type: COMPARATOR
Intervention: Incomplete Freund's adjuvant (IFA)
Number of subjects: 48
Study: 3243304

Group type: EXPERIMENTAL
Intervention: Six-week intensive cardiac rehabilitation programme
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 30926955

Group type: COMPARATOR
Intervention: IBT-liraglutide
Number of subjects: 113

Group type: COMPARATOR
Intervention: Multi-component
Number of subjects: 113

Group type: COMPARATOR
Intervention: IBT-alone
Number of subjects: 113
Study: 29396153

Group type: EXPERIMENTAL
Intervention: Nutrition‐ and physical activity‐enhanced Parents as Teachers curriculum
Number of subjects: 54

Group type: COMPARATOR
Intervention: Parents as Teachers curriculum
Number of subjects: 54
Study: 29056859

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 5 μg/h titrated to 20 μg/h, once weekly for 6 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Oral tramadol/acetaminophen (TA) 37.5 mg/325 mg, titrated to 4 tablets, twice daily for 6 weeks
Number of subjects: 87
Study: 25777980

Group type: EXPERIMENTAL
Intervention: Proactive blocking
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Retroactive unovershadowing
Number of subjects: 5

Group type: COMPARATOR
Intervention: Secondary memory task
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Proactive unovershadowing
Number of subjects: 5
Study: 24023492

Group type: EXPERIMENTAL
Intervention: BIS plus PEG‐CS
Number of subjects: 264

Group type: COMPARATOR
Intervention: 4‐L PEG
Number of subjects: 264
Study: 21129718

Group type: EXPERIMENTAL
Intervention: High-dose treatment (atorvastatin 80 mg/day)
Number of subjects: 18885

Group type: COMPARATOR
Intervention: Moderate-dose treatment (atorvastatin 10 mg/day in TNT and simvastatin 20 to 40 mg/day in IDEAL)
Number of subjects: 18885

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 18885

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 18885
Study: 19920722

Group type: EXPERIMENTAL
Intervention: LidoDin cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 40
Study: 16510622

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: BPAP
Number of subjects: 29
Study: 14632858

Group type: EXPERIMENTAL
Intervention: TR group (undescended testicle)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (inguinal hernia or appendicitis)
Number of subjects: 13
Study: 11090260

Group type: EXPERIMENTAL
Intervention: Encapsulated algae-derived DHA oil (0.57 g DHA/day) and fungal-derived AA oil (0.26 g AA/day) for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no supplements)
Number of subjects: 24
Study: 9323059

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829
Study: 8457236

Group type: EXPERIMENTAL
Intervention: Dried garlic powder (Sapec) 900 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2947095

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30893271

Group type: EXPERIMENTAL
Intervention: CD101 3% gel applied intravaginally on days 1 and 2
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CD101 6% ointment applied intravaginally on day 1
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oral fluconazole 150 mg on day 1
Number of subjects: 126
Study: 29954403

Group type: EXPERIMENTAL
Intervention: Cardiac Care Bridge transitional care program (CCB program)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 500
Study: 27436210

Group type: EXPERIMENTAL
Intervention: Nerve grafting procedures
Number of subjects: 2351

Group type: EXPERIMENTAL
Intervention: Inpatient procedure
Number of subjects: 2351

Group type: EXPERIMENTAL
Intervention: Longer operative time
Number of subjects: 2351

Group type: EXPERIMENTAL
Intervention: Worse wound classifications
Number of subjects: 2351

Group type: EXPERIMENTAL
Intervention: Any complications
Number of subjects: 2351
Study: 25118610

Group type: EXPERIMENTAL
Intervention: Magnesium carbonate plus calcium acetate as a phosphate binder (Mg group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Calcium acetate alone (Ca group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Magnesium carbonate plus calcium acetate (Mg group)
Number of subjects: 72
Study: 22651892

Group type: EXPERIMENTAL
Intervention: Symptom Coaching
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Test Coaching
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combined Coaching
Number of subjects: 103

Group type: COMPARATOR
Intervention: Best Effort Control
Number of subjects: 103
Study: 20491838

Group type: EXPERIMENTAL
Intervention: Marginal bone loss
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Peri-apical bone defect
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Constant length dehiscence
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Constant width dehiscence
Number of subjects: 32
Study: 17703457

Group type: EXPERIMENTAL
Intervention: External quality control (EQC) for liquid-based cytology
Number of subjects: 13

Group type: COMPARATOR
Intervention: ASCUS diagnosis
Number of subjects: 13
Study: 16029914

Group type: EXPERIMENTAL
Intervention: Alveolar vaccination
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bronchial vaccination
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intra-muscular vaccination (control)
Number of subjects: 30
Study: 11999549

Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract (61.8 mg of isoflavones)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9803068

Group type: EXPERIMENTAL
Intervention: Biozole (generic fluconazole)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diflucan (innovator fluconazole)
Number of subjects: 12
Study: 7634882

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Familiarization with gum
Number of subjects: 322
Study: 2233545

Group type: EXPERIMENTAL
Intervention: fancimef
Number of subjects: 49

Group type: COMPARATOR
Intervention: quinine combined with fansidar
Number of subjects: 49
Study: 678365

Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen and 0.93% halothane
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen and 1.30% enflurane
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen and 0.31% methoxyflurane
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen (control group)
Number of subjects: 22
Study: 30576030

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Present‐Centered Therapy (PCT)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Loss of diagnosis (both treatments)
Number of subjects: 235
Study: 27810568

Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Life Review (LR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waitlist Control (WC)
Number of subjects: 70
Study: 25623883

Group type: EXPERIMENTAL
Intervention: Bitter melon 2 g/day
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Bitter melon 4 g/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Glibenclamide 5 mg/day
Number of subjects: 95
Study: 23866185

Group type: EXPERIMENTAL
Intervention: Core Model of the Logistic Clinical SYNTAX score
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: Extended Model of the Logistic Clinical SYNTAX score
Number of subjects: 2627

Group type: COMPARATOR
Intervention: Anatomical SYNTAX score
Number of subjects: 2627
Study: 21704788

Group type: EXPERIMENTAL
Intervention: MCHS test
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: PPA fall risk scores
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Functional balance and mobility tests
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: MCHS and PPA scores
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Regular squatting
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Knee extension strength, single-leg stance ability, leaning balance
Number of subjects: 280
Study: 19217890

Group type: EXPERIMENTAL
Intervention: Plasma betaine concentrations
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Plasma dimethylglycine concentrations
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Urine betaine excretions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Urine dimethylglycine excretions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plasma betaine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plasma dimethylglycine and urine betaine
Number of subjects: 16
Study: 17710804

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment, applied once daily for 30 minutes, with 2-3 courses on average
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment for liver protection
Number of subjects: 60
Study: 15998769

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/d
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11972164

Group type: EXPERIMENTAL
Intervention: Formoterol 12 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Formoterol 24 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Salmeterol 50 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Salmeterol 100 mg
Number of subjects: 47
Study: 10357421

Group type: EXPERIMENTAL
Intervention: Galectin-3 expression in thyroid malignancies (papillary, follicular, and anaplastic carcinomas)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Galectin-3 expression in medullary carcinomas
Number of subjects: 172

Group type: COMPARATOR
Intervention: Galectin-3 expression in benign thyroid adenomas, goiters, and normal thyroid tissues
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Immunoblot analysis of galectin-3 in isolated epithelial cells from thyroid nodules
Number of subjects: 172
Study: 8602658

Group type: COMPARATOR
Intervention: Alfentanil at target concentrations of 0 ng/ml (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alfentanil at target concentrations of 50 ng/ml (Group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alfentanil at target concentrations of 200 ng/ml (Group C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alfentanil at target concentrations of 400 ng/ml (Group D)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alfentanil (0 to 500 ng/ml)
Number of subjects: 20
Study: 1777174

Group type: EXPERIMENTAL
Intervention: Zidovudine (250 mg every 6 h)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Combination of zidovudine and acyclovir (800 mg every 6 h)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 7324943

Group type: EXPERIMENTAL
Intervention: 1 alpha‐hydroxy‐vitamin D3, 0.05 or 0.10 micrograms/kg i.v. on the first 3 days of life
Number of subjects: 81

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 81
Study: 31454197

Group type: EXPERIMENTAL
Intervention: Continuous ventilation (Group 1, n=37)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Non-ventilated group (Group 2, n=37)
Number of subjects: 74
Study: 27792047

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexmedetomidine (20 ml ropivacaine 0.5% plus 1 ml dexmedetomidine 100 µg/ml)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ropivacaine plus placebo (20 ml ropivacaine 0.5% plus 1 ml saline)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexmedetomidine
Number of subjects: 21
Study: 26489511

Group type: EXPERIMENTAL
Intervention: Danhong injection
Number of subjects: 870

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study: 23413781

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (5/160 mg once a day for 3 days) plus hydration (1 mL/kg/h sodium chloride infusion for 24 hours)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hydration only (1 mL/kg/h sodium chloride infusion for 24 hours)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan plus hydration
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hydration only
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan plus hydration (in diabetic subgroup)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hydration only (in diabetic subgroup)
Number of subjects: 90
Study: 21454091

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with regular consultations with the dietitian and multidisciplinary team
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Age- and gender-matched controls
Number of subjects: 100

Group type: COMPARATOR
Intervention: Simple exercise advice
Number of subjects: 100
Study: 20046652

Group type: EXPERIMENTAL
Intervention: Focused, structured 9-month SMBG intervention (n=59)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Regular care based on guidelines (n=64)
Number of subjects: 159
Study: 17674975

Group type: EXPERIMENTAL
Intervention: WBRT+SRS
Number of subjects: 132

Group type: COMPARATOR
Intervention: SRS alone
Number of subjects: 132
Study: 14693982

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 3305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3305
Study: 12066082

Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other tocolytic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9620911

Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human IL-4
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (vehicle inhalation)
Number of subjects: 8
Study: 7907426

Group type: EXPERIMENTAL
Intervention: Formoterol (12 or 24 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2668247

Group type: EXPERIMENTAL
Intervention: Netilmicin 4.5 mg/kg once daily (od)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Netilmicin 1.5 mg/kg thrice daily (tid)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Netilmicin (od and tid)
Number of subjects: 114
Study: 324566

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 31